Bruker (BRKR) Scheduled to Post Quarterly Earnings on Tuesday

by · The Markets Daily

Bruker (NASDAQ:BRKR – Get Free Report) will be issuing its quarterly earnings data before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of $0.61 per share for the quarter. Bruker has set its FY24 guidance at $2.59-2.64 EPS and its FY 2024 guidance at 2.590-2.640 EPS.

Bruker (NASDAQ:BRKR – Get Free Report) last issued its earnings results on Tuesday, August 6th. The medical research company reported $0.52 EPS for the quarter, meeting analysts’ consensus estimates of $0.52. Bruker had a return on equity of 24.92% and a net margin of 11.29%. The business had revenue of $800.70 million during the quarter, compared to analyst estimates of $799.44 million. During the same period in the prior year, the company posted $0.50 earnings per share. Bruker’s revenue was up 17.4% on a year-over-year basis. On average, analysts expect Bruker to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Bruker Stock Performance

BRKR traded down $0.20 during trading on Tuesday, reaching $58.26. 57,255 shares of the company’s stock were exchanged, compared to its average volume of 1,043,438. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. The business has a 50 day moving average price of $64.74 and a 200 day moving average price of $67.57. Bruker has a fifty-two week low of $53.79 and a fifty-two week high of $94.86. The company has a market capitalization of $8.47 billion, a P/E ratio of 21.19, a PEG ratio of 2.52 and a beta of 1.18.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.34%. The ex-dividend date was Friday, August 30th. Bruker’s dividend payout ratio (DPR) is presently 7.27%.

Analyst Upgrades and Downgrades

BRKR has been the topic of several analyst reports. Wells Fargo & Company began coverage on Bruker in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price objective on the stock. The Goldman Sachs Group lowered their price target on Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a research report on Tuesday, July 9th. TD Cowen cut their price objective on Bruker from $74.00 to $72.00 and set a “hold” rating for the company in a report on Wednesday, August 7th. Citigroup reduced their target price on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, July 10th. Finally, Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $80.82.

View Our Latest Stock Analysis on Bruker

Bruker Company Profile

(Get Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Further Reading